Continuous Glucose Monitoring Beyond Diabetes: Expanding Clinical Applications and Insights

Abstract

Continuous glucose monitoring (CGM) technology, traditionally utilized for diabetes management, is gaining recognition for its potential in broader clinical contexts. This review explores the expanding applications of CGM beyond diabetes, highlighting recent evidence, mechanism-driven insights, and guideline-based recommendations. We synthesize current knowledge on epidemiology, pathophysiology, risk factors, clinical features, diagnostic utility, management strategies, emerging therapies, and future directions in the use of CGM for non-diabetic populations, aiming to inform clinicians regarding both established and investigational uses.

Introduction

Continuous glucose monitoring has revolutionized glycemic management in diabetes care, providing real-time data and actionable insights that surpass the limitations of conventional self-monitoring. However, the clinical utility of CGM is now extending into populations without diabetes, driven by growing evidence of dysglycemia's role in a spectrum of acute and chronic illnesses. This article critically examines the scientific rationale, current clinical applications, and emerging data supporting the use of CGM in patients beyond the traditional diabetic cohort, with a focus on pathophysiological mechanisms, practical implementation, and future clinical implications.

Epidemiology / Disease Burden

Glycemic variability and unrecognized episodes of hypoglycemia or hyperglycemia are increasingly recognized among hospitalized patients, critically ill individuals, those with endocrine disorders other than diabetes, and even ostensibly healthy subjects. Studies indicate that up to 30% of critically ill patients without pre-existing diabetes experience significant dysglycemia, which correlates with higher morbidity and mortality rates. Similarly, gestational dysglycemia, cystic fibrosis-related glucose intolerance, and medication-induced hyperglycemia contribute to a substantial, often underappreciated, disease burden. The prevalence of metabolic syndrome and obesity further broadens the population potentially benefiting from CGM, as impaired glucose regulation often precedes overt diabetes.

Pathophysiology

CGM elucidates dynamic glucose fluctuations driven by complex interactions between insulin secretion, insulin sensitivity, counter-regulatory hormones, and external stressors. In critical illness, stress-induced hyperglycemia results from catecholamine release, inflammatory cytokines, and relative insulin resistance, while hypoglycemia may arise from impaired gluconeogenesis or excessive exogenous insulin. In non-diabetic individuals, postprandial glycemic excursions and nocturnal hypoglycemia often go undetected with intermittent testing. CGM enables continuous assessment of these fluctuations, providing mechanistic insights into their occurrence and potential impact on organ function, metabolic stability, and overall prognosis.

Risk Factors

Key risk factors for dysglycemia in non-diabetic populations include acute illness (sepsis, trauma, myocardial infarction), use of glucocorticoids or other hyperglycemia-inducing agents, pre-existing metabolic syndrome, obesity, chronic liver or renal disease, pregnancy (particularly gestational diabetes risk), endocrine disorders (e.g., Cushing’s syndrome, acromegaly), and advanced age. Understanding these risk factors is critical for identifying patients who may benefit from CGM-based monitoring and intervention, as conventional risk stratification may underestimate glycemic instability in these groups.

Clinical Features

While overt symptoms of dysglycemia (e.g., confusion, diaphoresis, palpitations in hypoglycemia; polyuria, polydipsia, fatigue in hyperglycemia) may occur, many episodes are clinically silent particularly in hospitalized or sedated patients. CGM uncovers asymptomatic glycemic excursions, postprandial spikes, and nocturnal hypoglycemia, which are associated with adverse outcomes such as delirium, infection, prolonged hospitalization, and increased mortality, even in non-diabetic individuals. The detection of subclinical dysglycemia has important implications for risk assessment and proactive management.

Diagnosis

CGM provides a comprehensive temporal profile of interstitial glucose levels, capturing fluctuations that traditional point-in-time glucose measurements or HbA1c testing may miss. In non-diabetic subjects, CGM can identify impaired glucose tolerance, stress-induced hyperglycemia, and occult hypoglycemia, facilitating earlier diagnosis and targeted intervention. Diagnostic thresholds for intervention are evolving, with recent guidelines suggesting the need for individualized targets based on clinical context and comorbidities.

Treatment & Management

In acute care settings, CGM informs insulin titration, nutritional interventions, and avoidance of iatrogenic hypoglycemia. For patients at risk of medication-induced dysglycemia, CGM enables timely adjustment of therapy. In metabolic syndrome, obesity, and prediabetes, CGM feedback can guide lifestyle modifications and pharmacological strategies to mitigate progression to diabetes. Furthermore, CGM use in pregnancy allows for real-time detection and management of gestational dysglycemia, optimizing fetal and maternal outcomes. The integration of CGM data into electronic health records facilitates multidisciplinary collaboration and individualized care planning.

Recent Advances / Emerging Therapies

Technological advancements have improved CGM accuracy, usability, and integration with digital health platforms. Recent studies highlight the utility of CGM in intensive care units, perioperative management, and even in athletes to optimize metabolic performance. Emerging research supports the role of CGM in assessing the real-time impact of novel therapies (e.g., SGLT2 inhibitors, GLP-1 agonists) on glycemic variability in non-diabetic populations. Algorithm-driven closed-loop systems, although primarily used in diabetes, are being investigated for broader clinical use, potentially transforming inpatient glycemic management.

Guideline Recommendations

Professional societies, including the American Diabetes Association and the Endocrine Society, increasingly recognize the role of CGM beyond diabetes, particularly in hospital and perioperative settings, pregnancy, and high-risk populations. Guidelines recommend individualized CGM use for patients with unexplained hypoglycemia, critical illness, or high glycemic variability, while emphasizing the need for clinician training, data interpretation, and integration into broader care pathways. Ongoing trials and registry data are expected to inform future guideline updates.

Conclusion

Continuous glucose monitoring is rapidly transcending its origins in diabetes care, offering unprecedented opportunities to detect, understand, and manage dysglycemia in a wide array of clinical contexts. As technology advances and evidence accumulates, CGM is poised to become an integral tool for risk stratification, therapeutic optimization, and personalized medicine well beyond the diabetic population. Continued research, multidisciplinary collaboration, and evidence-based guidelines will be essential to realize the full potential of CGM in improving patient outcomes across diverse healthcare settings.